Targeted estrogen/progestogen replacement therapy for osteoporosis: calculation of health care cost savings
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Osteoporosis is a crippling affliction in which bone mass decreases, making it more susceptible to fracture. In postmenopausal women it presents most often as a hip, spinal, or forearm fracture. Adult women face a 15% lifetime risk of a hip fracture, and the annual costs of hip fractures alone are estimated at $7.3 billion in the United States. Since the 1970s, estrogen/progestogen therapy has been recognized as an effective intervention that reduces the risk of fractures. Recently, the development of methods for accurately determining bone mass and thus helping to predict bone fracture risk has made this intervention attractive for use in a targeted population.
This report analyzes the health care costs and calculates the cost savings of coupling bone mineral density screening at the time of menopause with long-term estrogen/progestogen therapy for those most at risk for developing fractures. The model assumes that a cohort of 100000 American white women, aged 50, are screened for bone mineral density and that 90% of the high-risk group (density <0.85 g/cm3) and 70% of the mid-risk group (density between 0.85 and 1.00 g/cm3) elect to take hormone replacement therapy for 15 years. Based on calculations of the costs of screening and hormone replacement therapy, and the savings in cost of treatment and lost productivity from reduced fractures, it is estimated that the present value of savings in cost of illness for this cohort over a 40-year period is $5.1 million. In present value terms, total net savings of $27.6 million attributable to screening and hormonal therapy are projected, over a 40-year period, assuming that 50% of the 1.09 million American white women who reached age 50 in 1988 are screened as described for the cohort. Similar, if not greater, savings could be expected for populations reaching age 50 in subsequent years.
- Report of the Task Force of the National Osteoporosis Foundation. Clinical indications for bone mass measurements. J Bone Miner Res 1989; 4 Suppl 2:1–28.
- Albright, F, Smith, PH, Richardson, AM (1941) Postmenopausal osteoporosis. JAMA 116: pp. 2465-74
- Hutchinson, TA, Polansky, AM, Feinstein, AR (1979) Postmenopausal oestrogens protect against fractures of hip and distal radius. Lancet 2: pp. 705-9
- Weiss, NS, Ure, CL, Ballard, JH, Williams, AR, Daling, JR (1980) Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogen. N Engl J Med 303: pp. 1195-8
- Krieger, N, Kelsey, JL, Holford, TR, O'Connor, T (1982) An epidemiologic study of hip fracture in postmenopausal women. Am J Epidemiol 116: pp. 141-8
- Kiel, DP, Felson, DT, Anderson, JJ, Wilson, PWF, Moskowitz, M (1987) Hip fracture and the use of estrogens in postmenopausal women. N Engl J Med 317: pp. 1169-74
- Ettinger, B, Genant, HK, Cann, CE (1985) Long-term estrogen replacement therapy prevents bone loss and fractures. Ann Intern Med 102: pp. 319-24
- Recker, RR, Saville, PD, Heaney, RP (1977) Effect of estrogens and calcium carbonate on bone loss in postmenopausal women. Ann Intern Med 87: pp. 649-55
- Quigley, MET, Matrin, PL, Burnier, AM, Brooks, P (1982) Estrogen therapy arrests bone loss in elderly women. Am J Obstet Gynecol 156: pp. 1516-23
- Al-Azzawi, F, Hart, DM, Lindsay, R (1987) Long term effect of oestrogen replacement therapy on bone mass as measured by dual photon absorptiometry. Br Med J 294: pp. 1261-2
- Smith, DC, Prentice, R, Thompson, DJ, Herrmann, WL (1975) Association of exogenous estrogen and endometrial carcinoma. N Engl J Med 293: pp. 1164-7
- Persson, I, Adami, H-O, Berkvist, L (1989) Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens: results of a prospective study. Br Med J 298: pp. 147-51
- Melton, LJ, Kan, SH, Frye, MA, Wahner, HW, O'Fallon, WM, Riggs, BL (1989) Epidemiology of vertebral fractures in women. Am J Epidemiol 129: pp. 1000-11
- Gardsell, P, Johnell, O, Nilsson, BE (1989) Predicting fractures in women by using forearm bone densitometry. Calcif Tissue Int 44: pp. 235-42
- Hui, SL, Slemenda, CW, Johnston, CC (1989) Baseline measurement of bone mass predicts fracture in white women. Ann Intern Med 111: pp. 355-61
- Wasnich, RD, Ross, PD, Heilbrun, LK, Vogel, JM (1985) Prediction of postmenopausal fracture risk with use of bone mineral measurements. Am J Obstet Gynecol 153: pp. 745-51
- Tosteson, ANA, Rosenthal, DI, Melton, LJ, Weinstein, MC (1990) Cost effectiveness of screening perimenopausal white women for osteoporosis: bone densitometry and hormone replacement therapy. Ann Intern Med 113: pp. 594-603
- Farmer, ME, White, LR, Brody, JA, Bailey, KR (1984) Race and sex difference in hip fracture incidence. Am J Public Health 74: pp. 1374-80
- Sources of statistical data: Statistical abstract of the United States 1990, US Department of Commerce, Bureau of the Census; Hospital statistics, 1989–1990 edn, data from the American Hospital Association 1988 annual survey (1989), American Hospital Association, Chicago, Illinois.
- Holbrook, TL, Grazier, K, Kelsey, JL, Stauffer, RN (1984) The frequency of occurrence, impact and cost of selected musculoskeletal conditions in the United States. American Academy of Orthopaedic Surgeons, Chicago
- Medicare reimbursement for bone mass measurement. National Osteoporosis Foundation, August 1990.
- Targeted estrogen/progestogen replacement therapy for osteoporosis: calculation of health care cost savings
Volume 2, Issue 4 , pp 195-200
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Bone mineral density screening
- Health care costs
- Hip fracture
- Hormone replacement therapy
- Industry Sectors
- Author Affiliations
- 1. Division of Research Grants, National Institutes of Health, 5333 Westbard Ave., Rm. A10, 20892, Bethesda, MD, USA
- 2. Office of Science Policy and Legislation, Office of the Director, National Institutes of Health, Bethesda, Maryland, USA